Namzaric (Memantine HCl/Donepezil HCl) Patent Expiration, LOE Window & CMS Spending

Namzaric (Memantine HCl/Donepezil HCl) by AbbVie: FDA Orange Book LOE 2029-12-05, 4 AB generics, $90.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN206439 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-12-05
Orange Book Patents (*PED Extensions)3 patents (1 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$90.8M
2024 Medicare Part D Spend$89.6M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.